Nathaniel Dahan

Nathaniel Dahan is a Principal of Syncona Investment Management Limited.

He is a Director on the Board of Forcefield Therapeutics and Apini Therapeutics, and was closely involved in the foundation of Slingshot Therapeutics. He is also a board observer on Beacon Therapeutics.

Before joining Syncona, Nathaniel was part of the Life Sciences M&A Consulting team at Deloitte, focusing on the preparation and execution of large pharma and medtech acquisitions and separations. His background includes strategy execution consulting in pharma, healthcare and other industries, as well as strategic communications for biotech and medtech start-ups.

Nathaniel has a PhD in Biomedical Engineering from University College London and was also a postdoctoral researcher at Imperial College London and King's College London.